Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma

NCT00591058 is registered in ClinicalTrials.gov with TransMolecular as lead sponsor.

NCT NCT00591058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00591058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma
Lead sponsor
TransMolecular
Phase
Phase 1
Overall status
Unknown status
Start date
February 29, 2008
Completion date
February 28, 2010
Enrollment
36 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, gbm, glioblastoma multiforme, malignant glioma, oligodendroglioma